INTRODUCTION AND OBJECTIVES:
We previously found no mortality differences between surgery and observation in men with localized prostate cancer through 12 years. Uncertainty persists regarding nonfatal health outcomes and long-term mortality. We evaluated clinically important outcomes for men with early stage prostate cancer diagnosed during the early PSA era who were randomly assigned to treatment with either surgery or observation.
METHODS: Between 1994 and 2002, we randomly assigned 731 men with localized prostate cancer to radical prostatectomy or observation. We extended follow-up through August 2014 for our primary outcome, all-cause mortality, and main secondary outcome, prostate cancer mortality. We describe disease progression, additional treatments received and patient reported outcomes through the original follow-up of January 2010.
RESULTS: During 19.5 years of follow-up (Median¼12.7 years), 223 of 364 men (61.3%) assigned to surgery died compared to 245 of 367 (66.8%) assigned to observation; (Absolute risk reduction(ARR)¼5.5%, 95% Confidence Interval[CI], -1.5, 12.4); Hazard ratio(HR)¼0.84, 95%CI, 0.70, 1.01; P¼0.06). Prostate cancer mortality occurred in 27 men (7.4%) randomized to surgery versus 42 men (11.4%) randomized to observation; (ARR ¼ 4.0, 95%CI, -0.2 to 8.3; HR¼0.63, 95% CI, 0.39 to 1.02; P¼0.06). The effect of surgery on mortality did not vary by baseline patient characteristics. Radical prostatectomy may have reduced all-cause mortality among men with intermediate (ARR¼14.5%, 95%CI, 2.8 to 25.6) but not low (ARR¼0.6%, 95%CI, -10.5 to 11.8) or high risk disease (ARR¼2.3%, 95%CI, -11.5 to 16.1)(P for interaction ¼ 0.08). Surgery reduced disease progression treatment, primarily androgen deprivation for asymptomatic, local or PSA progression, by 26.2 percentage points(95%CI, 19.0 to 32.9). Urinary incontinence, erectile and sexual dysfunction were each greater by more than 30 percentage points with surgery. Disease or treatment related bother and limitations in activities of day-to-day living were greater with surgery though 2 years but not at later follow-up.
CONCLUSIONS: After nearly 20 years, surgery did not significantly reduce all-cause or prostate cancer mortality compared with observation. Surgery had more adverse effects, but reduced disease progression and subsequent treatments; most asymptomatic, local or biochemical and may have reduced all-cause mortality in men with intermediate risk disease.
Source of Funding: Department of Veterans Affairs, Agency for Healthcare Quality and Research and the National Cancer Institute.
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TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 EXPRESSING BLADDER CANCER USING COMBINATION PHOTOIMMUNOTHERAPY (PIT) mohammad siddiqui*, bethesda, MD; Reema Railkar, Thomas Sanford, Peter Choyke, Hisataka Kobayashi, Piyush Agarwal, Bethesda, MD INTRODUCTION AND OBJECTIVES: Bladder cancer (BC) is heterogeneous, expressing various cell surface targets, such as EGFR and Her2. Photoimmunotherapy (PIT) involves antibodies (Abs) conjugated to a photoabsorber (PA), IR Dye 700Dx, and then activated by Near infra-red light (NIR) to specifically target tumors. Our lab has previously shown that tumors expressing high levels of EGFR can be efficiently targeted with PIT. However, PIT is less effective when a tumor lacks "overwhelming" expression of a single target. Here, we present a novel, combinatorial PIT approach for such tumors expressing EGFR and Her2, using Panitumumab-IR700 (PanIR700) and Trastuzumumab-IR700 (TraIR700) antibodies, respectively.
METHODS: BC cell lines were analyzed for expression of EGFR and Her2 using flow cytometery. Concurrent and optimal binding of both PA-labeled Abs were determined using flow cytometery. NIR LD50 of multiple treatment regimens were determined to analyze in vitro efficacy of combination PIT.
RESULTS: The SW780 and RT112 cell lines showed low to moderate expression of EGFR and Her2. The EGFR expression was 143 fold higher in SW780 and 83 fold higher in RT112 over the isotype control. The Her2 expression was 42 fold higher in SW780 and 27 fold higher in RT112 over the isotype control. Hence, the ratio of cell surface EGFR to Her2 expression in both cell lines was about 3:1. For SW780, NIR LD50 was 28.66 J/cm2 for the combination PIT compared to 71.55 J/cm2 for the PanIR700 alone therapy. The NIR LD50 for RT112 was 14.66 J/cm2 for the combination PIT, with LD50 for PanIR700 alone therapy indeterminate from insufficient cell death. In both cases, the LD50 for TraIR700 alone therapy could not be determined from lack of sufficient cell death.
CONCLUSIONS: PIT is a new targeted treatment for bladder cancer that can be effectively used either locally or for metastatic lesions accessible by the NIR light. We demonstrate a novel and promising approach to treating BC by selectively inducing cell death in BC cell lines with low to moderate expression of cell surface markers of EGFR and Her2 using combination PIT. This will be further evaluated in a xenograft model. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e915 their defective retinoblastoma pathway. Prior reports have shown promising activity in patients with high-grade NMIBC who previously did not respond to BCG. However, limited accrual has hindered analysis of efficacy, particularly for pathologic subsets. We evaluated interim results of a phase II trial for intravesical CG0070 in patients with BCGunresponsive NMIBC who refused cystectomy. METHODS: At interim analysis, thirty-six patients with residual high grade Ta, T1, or CIS AE Ta/T1 had 6 month follow-up in this phase II single arm multicenter trial (NCT02365818). All patients received at least 2 prior courses of intravesical therapy for CIS, with at least 1 of them being a course of BCG. Patients had either failed BCG induction therapy within 6 months or had been successfully treated with BCG with subsequent recurrence. Complete response (CR) at 6 months was defined as absence of disease on cytology, cystoscopy, and random biopsies.
RESULTS: Of 36 patients there were 18 CIS, 4 CIS + Ta, 3 CIS + T1, 8 Ta, 3 T1 (Figure 1 ). Overall 6 month CR was 44%. Considering 6 month CR for pathologic subsets: pure CIS was 72.2%, CIS AE Ta/T1 52%, CIS + Ta/T1 0%, pure Ta/T1 27%. In non-responders with CIS, there were 4 patients (22%) with persistent CIS at 6 months, and 1 (5.6%) that progressed to CIS + T1. No patients with pure T1 or CIS + Ta/T1 had 6-month CR. In patients with both CIS + Ta/T1 (n¼7), 5 had persistent Ta/T1 AE CIS, while 2 had CIS on biopsy at 6 months. All treatment related adverse events (AEs) at 6 months were Grade 1-3, most commonly urinary: dysuria (47%), bladder spasms (44%), hematuria (36%), and urgency (33%). Immunologic treatment related AEs included fatigue (11%) and chills (5.6%). Grade 3 treatment related AEs included dysuria (5.6%) and hypotension (2.7%). There were no Grade 4/5 treatment related AEs.
CONCLUSIONS: This phase II study demonstrates that intravesical CG0070 yielded an overall 44% complete response rate at 6 months for all patients and 52% for patients with CIS, with an acceptable level of toxicity for patients with high-risk BCG-unresponsive NMIBC. There is a particularly strong response and limited progression in patients with pure CIS.
Source of Funding: Cold Genesys

PNFLBA-14 EARLY IN VIVO DETECTION OF METASTATIC BLADDER CANCER IN MICE USING MOLECULAR MRI
Joel Slaton*, Saint Louis, MO; Nataliya Smith, Debra Saunders, Robert Hurst, Rheal Towner, Oklahoma City, OK INTRODUCTION AND OBJECTIVES: Early detection of bladder cancer metastases might provide the potential for early treatment of metastatic disease. We previously reported on the use of a bladder tumor-binding peptide (BTBP)2 coupled to a Gd-DOTA MRI contrast agent (BTBP-probe)3 delivered intravesically to visualize bladder cancer growing on the bladder surface of an orthotopic mouse model, In this new report we demonstrated the use of this probe delivered intravenously to detect micrometastic spread of cancer to distant organs. METHODS: MRI Studies: MRI experiments were done on a Bruker Biospec 7.0 Tesla/30 cm horizontal-bore imaging system. Multiple abdominal region 1H-MR image slices were taken using a RARE multislice (repetition time (TR) 1.3 s, echo time (TE) 9 ms, 256x256 matrix, 4 steps per acquisition, 3x3 cm2 field of view, 0.75 mm slice thickness). Mouse abdominal organs were imaged at 0 (pre-contrast) and at 3-4 hours post-contrast agent injection. Mice were injected intravenously with the BTBP-Gd-DOTA contrast agent (100ml/mouse; 50mmol/L). T1-weighted images were obtained using a variable TR (repetition time) spin-echo sequence (TR, 200-1600 ms; TE, 15 ms; NA, 2). Pixel-by-pixel relaxation maps were reconstructed from a series of T1-weighted images using a nonlinear two-parameter fitting procedure. The T1 value of a specified region-of-interest (ROI) was computed from all the pixels in the identified ROIs. MRI scans were obtained 6-7 weeks post-implantation of bladder tumors to identiy metastatic lesions.
RESULTS: Molecular MRI (mMRI) was used to detect the presence of the BTBP-probe via a substantial decrease in T1 relaxation, measured as T1 relaxation difference, within tumor regions of mice administered the BTBP-probe (p<0.05) compared to the controls. Both primary and metastatic tumors were detected.
CONCLUSIONS: We used mMRI to show for the first time noninvasive in vivo early detection of bladder tumor metastases in a mouse model for bladder carcinoma. Using mMRI with a bladder tumor-binding peptide targeted probe provides the advantage of in vivo image resolution and spatial differentiation of regional events in early detection of bladder cancer metastases. Alan Partin*, Baltimore, MD; Phillipp Torkler, Mikkel Noerholm, Martinsried, Germany; Johan Skog, Cambridge, MA; Michael Donovan, NYC, NY INTRODUCTION AND OBJECTIVES: Overdetection and overtreatment of indolent prostate cancer (PCa) remains a significant health issue requiring noninvasive assays to guide the prostate biopsy decision process. We previously demonstrated that a non-DRE urine exosome gene expression assay (ExoDx Prostate (IntelliScore) (EPI) discriminates GS 7 PCa from GS 6 and benign disease, potentially reducing the number of unnecessary biopsies. We initiated a novel prospective, phase-adaptive two cohort trial design: Group 1 (G1), men scheduled for a biopsy and Group 2 (G2), men for which the decision to biopsy is uncertain. The G1 consensus results including EPI cut-point recommendation will be applied to G2 patients with clinical utility, ease of adoption, patient response and health economic data collected. Here we report interim results from G1 with initial cut-point comparison to the original validation trial.
Source of
METHODS: The trial was activated on Sept. 2016 at 9 sites (8 community practice, 1 academic), geographically distributed across the U.S. We plan to enlist up to 20 sites by April 2017. Enrollment is limited to initial biopsy patients only, >/¼50 years with PSA 2-10 ng/mL. The EPI test is performed at Exosome Diagnostics' CLIA laboratory in Cambridge, MA; G1 results are collected for consensus review and G2 recommendation.
RESULTS: The average biopsy rate across all sites is 1-2 / week. Demographics of the 96 (of targeted) 500 G1 patients enrolled thus far are comparable to the validation study (mean age 64 years, mean PSA 5.78; 75% white, 17% African American, 23% positive family history of PCa, 81% non-suspicious DRE). Of note, we have observed a higher positive biopsy rate of 59% (vs. 47% in validation study); 22% ISUP 1 (GS 3+3) and 37% >/¼ISUP 2. The EPI test validated (15.6) vs.
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